PCN91 BEVACIZUMAB + PACLITAXEL + CARBOPLATIN (BEV + PAC + CAR) VS. PEMETREXED + CISPLATIN (PEM + CIS) IN ADENOCARCINOMA NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COST-EFFECTIVENESS ANALYSIS FROM A POLISH PUBLIC PAYER'S PERSPECTIVE

PCN91 BEVACIZUMAB + PACLITAXEL + CARBOPLATIN (BEV + PAC + CAR) VS. PEMETREXED + CISPLATIN (PEM + CIS) IN ADENOCARCINOMA NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COST-EFFECTIVENESS ANALYSIS FROM A POLISH PUBLIC PAYER'S PERSPECTIVE

Saved in:
Bibliographic Details
Published in:Value in health Vol. 13; no. 7; p. A268
Main Authors: Kawalec, P, Badurak, P, Denisso, T, Jastrzebski, D, Marek, M, Pluzanski, A, Szczesna, A, Szkultecka-Debek, M, Russel-Szymczyk, M
Format: Journal Article
Language:English
Published: Elsevier Inc 2010
Subjects:
Internal Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:1098-3015
1524-4733
DOI:10.1016/S1098-3015(11)71986-6